The Two Faces of Galectin-3: Roles in Various Pathological Conditions
By:
References
- 1. Liu FT, Rabinovich GA. (2005). Galectins as modulators of tumour progression. Nat Rev Cancer, 5(1), 29-41.
- 2. Radosavljevic G, Volarevic V, Jovanovic I, Milovanovic M, Pejnovic N, Arsenijevic N, et al. (2012). The roles of Galectin-3 in autoimmunity and tumor progression. Immunol Res, 52,100–110.
- 3. Moutsatsos IK, Wade M, Schindler M, Wang JL. (1987). Endogenous lectins from cultured cells: nuclear localization of carbohydrate binding protein 35 in proliferating 3T3 fibroblasts. Proc Natl Acad Sci USA, 84, 6452–6456.
- 4. Yu F, Finley R, Raz A, Kim H-RC. (2002). Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J Biol Chem, 277(18), 15819–15827.
- 5. Paron I, Scaloni A, Pines A, Bachi A, Liu F-T, Puppin C, et al. (2003). Nuclear localization of Galectin-3 in transformed thyroid cells:a role in transcriptional regulation. Biochem Biophys Res Commun, 302(3), 545–553.
- 6. Dagher SF, Wang JL, Patterson RJ. (1995). Identification of galectin-3 as a factor in pre-mRNA splicing. Proc Natl Acad Sci USA, 92(4), 1213–1217.
- 7. Wang JL, Gray RM, Haudek KC, Patterson RJ. (2004). Nucleocytoplasmic lectins. Biochim Biophys Acta, 1673(1–2), 75–93.
- 8. Yang RY, Hsu DK, Liu FT. (1996). Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci USA, 93, 6737–6742.
- 9. Califice S, Castronovo V, Bracke M, van den Brûle F. (2004). Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene, 23(45), 7527–7536.
- 10. Nakahara S, Oka N, Raz A. (2005). On the role of galectin-3 in cancer apoptosis. Apoptosis, 10(2), 267–275.
- 11. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, et al. (1998). Two CD95 (APO-1/Fas) signaling pathways. EMBO J, 17(6), 1675-1687.
- 12. Fukumori T, Takenaka Y, Oka N, Yoshii T, Hogan V, Inohara H, et al. (2004). Endogenous galectin-3 determines the routing of CD95 apoptotic signaling pathways. Cancer Res, 64(10), 3376-3379.
- 13. Hsu DK, Chen HY, Liu FT. (2009). Galectin-3 regulates T-cell functions. Immunol Rev, 230(1), 114-127.
- 14. Dumic J, Dabelic S, Flögel M. (2006). Galectin-3: an open-ended story. Biochim Biophys Acta, 1760, 616–635.
- 15. Funasaka T, Raz A, Nangia-Makker P. (2014). Galectin-3 in angiogenesis and metastasis. Glycobiology, 24(10), 886–891.
- 16. Yu L-G. (2010). Circulating galectin-3 in the blood-stream: An emerging promoter of cancer metastasis. World J Gastrointest Oncol, 2(4), 177-180.
- 17. Braeuer RR, Shoshan E, Kamiya T, Bar-Eli M. (2012). The sweet and bitter sides of galectins in melanoma progression. Pigment Cell Melanoma Res, 25(5), 592-601.
- 18. Sano H, Hsu DK, Yu L, Apgar JR, Kuwabara I, Yamanaka T, et al. (2000). Human galectin-3 is a novel chemoattractant for monocytes and macrophages. J Immunol, 165, 2156–2164.
- 19. Ochieng J, Leite-Browning ML, Warfield P. (1998). Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Biochem Biophys Res Commun, 246, 788–791.
- 20. Demetriou M, Granovsky M, Quaggin S, Dennis JW. (2001). Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature, 409, 733–739.
- 21. Breuilh L, Vanhoutte F, Fontaine J, van Stijn CM, Tillie-Leblond I, Capron M, et al. (2007). Galectin-3 modulates immune and inflammatory responses during helminthic infection: impact of galectin-3 deficiency on the functions of dendritic cells. Infect Immun, 75, 5148–5157.
- 22. Wu SY, Yu JS, Liu FT, Miaw SC, Wu-Hsieh BA. (2013). Galectin-3 negatively regulates dendritic cell production of IL-23/IL-17-axis cytokines in infection by Histoplasma capsulatum. J Immunol, 190, 3427–3437.
- 23. Cortegano I, del Pozo V, Cárdaba B, de Andrés B, Gallardo S, del Amo A et al. (1998). Galectin-3 down-regulates IL-5 gene expression on different cell types. J Immunol, 161, 385–389.
- 24. Ruas LP, Bernardes ES, Fermino ML, de Oliveira LL, Hsu DK, Liu FT. et al. (2009). Lack of galectin-3 drives response to Paracoccidioides brasiliensis toward a Th2-biased immunity. PLoS One, 4, e4519.
- 25. Bernardes ES, Silva NM, Ruas LP, Mineo JR, Loyola AM, Hsu DK, et al. (2006). Toxoplasma gondii infection reveals a novel regulatory role for galectin-3 in the interface of innate and adaptive immunity. Am J Pathol, 168, 1910–1920.
- 26. Ochieng J, Furtak V, Lukyanov P. (2004). Extracellular functions of galectin-3. Glycoconj J, 19, 527–535.
- 27. Mishra BB, Li Q, Steichen AL, Binstock BJ, Metzger DW, Teale JM, et al. (2013). Galectin-3 functions as an alarmin: pathogenic role for sepsis development in murine respiratory tularemia. PLoS One, 8(3), e59616.
- 28. Iacobini C, Menini S, Oddi G, Ricci C, Amadio L, Pricci F, et al. (2004). Galectin-3/AGE-receptor 3 knockout mice show accelerated AGE-induced glomerular injury: evidence for a protective role of galectin-3 as an AGE receptor. FASEB Journal, 18, 1773–1775.
- 29. Pejnovic NN, Pantic JM, Jovanovic IP, Radosavljevic GD, Djukic ALj, Arsenijevic NN, et al. (2013). Galectin-3 is a regulator of metaflammation in adipose tissue and pancreatic islets. Adipocyte, 2(4), 266-271.
- 30. Vlassara H, Li YM, Imani F, Wojciechowicz D, Yang Z, Liu FT et al. (1995). Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med, 1, 634–646.
- 31. Karlsen AE, Størling ZM, Sparre T, Larsen MR, Mahmood A, Størling J, et al. (2006). Immune-mediated beta-cell destruction in vitro and in vivo-A pivotal role for galectin-3. Biochem Biophys Res Commun, 344, 406-415.
- 32. Pejnovic NN, Pantic JM, Jovanovic IP, Radosavljevic GD, Milovanovic MZ, Nikolic IG, et al. (2013). Galectin-3 deficiency accelerates high-fat diet-induced obesity and amplifies inflammation in adipose tissue and pancreatic islets. Diabetes, 62(6), 1932-1944.
- 33. MacKinnon AC, Farnworth SL, Hodkinson PS, Henderson NC, Atkinson KM, Leffler H, et al. (2008). Regulation of alternative macrophage activation by galectin-3. J Immunol, 180, 2650–2658.
- 34. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. (2010). Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol, 11, 136–140.
- 35. Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, et al. (2011). The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med, 17,179-188.
- 36. Angulo P. (2007). Obesity and nonalcoholic fatty liver disease. Nutr Rev, 65, S57–S63.
- 37. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. (2012). The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the american associations for the study of liver diseases, American college of gastroenterology, and the American gastroenterologycal association. Hepatology, 55(6), 2005-2023.
- 38. Pugliese G, Iacobini C, Pesce CM, Menini S. (2015). Galectin-3: an emerging all-out player in metabolic disorders and their complications. Glycobiology, 25(2), 136-150.
- 39. Rhodes DH, Pini M, Castellanos KJ, Montero-Melendez T, Cooper D, Perretti M, et al. (2013). Adipose tissue specific modulation of galectin expression in lean and obese mice: Evidence for regulatory function. Obesity (Silver Spring), 21, 310-319.
- 40. Butscheid M, Hauptvogel P, Fritz P, Klotz U, Alscher D. (2007). Hepatic expression of Galectin-3 and RAGE in patients with liver disease. J Clin Pathol, 60, 415–418.
- 41. Jeftic I, Jovicic N, Pantic J, Arsenijevic N, Lukic ML, Pejnovic N. (2015). Galectin-3 Ablation Enhances Liver Steatosis, but Attenuates Inflammation and IL-33-Dependent Fibrosis in Obesogenic Mouse Model of Nonalcoholic Steatohepatitis. Mol Med, 21, 453-465.
- 42. Volarevic V, Milovanovic M, Ljujic B, Pejnovic N, Arsenijevic N, Nilsson U, et al. (2012). Galectin-3 deficiency prevents concanavalin A-induced hepatitis in mice. Hepatology, 55(6), 1954-1964.
- 43. Tiegs G, Hentschel J, Wendel A. (1992). A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest, 90(1), 196–203.
- 44. Kaplan MM, Gershwin ME. (2005). Primary biliary cirrhosis. The New England Journal of Medicine, 353(12), 1261–1273.
- 45. Gershwin ME, Mackay IR. (2008). The causes of primary biliary cirrhosis: Convenient and inconvenient truths. Hepatology, 47(2), 737-745.
- 46. Chuang YH, Lan RY, Gershwin ME. (2009). The immunopathology of human biliary cell epithelium. Semin Immunopathol, 31,323-331.
- 47. Kimura Y, Leung PS, Kenny TP, Van De Water J, Nishioka M, Giraud AS, et al. (2002). Differential expression of intestinal trefoil factor in biliary epithelial cells of primary biliary cirrhosis. Hepatology, 36(5), 1227-1235.
- 48. Sasaki M, Nakanuma Y. (2010). Biliary Epithelial Apoptosis, Autophagy, and Senescence in Primary Biliary Cirrhosis. Hepatitis Research and Treatment, 2010, 205128.
- 49. Mensah-Brown EP, Al Rabesi Z, Shahin A, Al Shamsi M, Arsenijevic N, Hsu DK, et al. (2009). Targeted disruption of the galectin-3 gene results in decreased susceptibility to multiple low dose streptozotocin-induced diabetes in mice. Clin Immunol, 130, 83-88.
- 50. Jiang HR, Al Rasebi Z, Mensah-Brown E, Shahin A, Xu D, Goodyear CS, et al. (2009). Galectin-3 deficiency reduces the severity of experimental autoimmune encephalomyelitis. J Immunol, 182, 1167-1173.
- 51. Takenaka Y, Fukumori T, Raz A. (2004). Galectin-3 and metastasis. Glycoconj J, 19, 543-549.
- 52. Miyazaki J, Hokari R, Kato S, Tsuzuki Y, Kawaguchi A, Nagao S, et al. (2002). Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes. Oncol Rep, 9(6), 1307-1312.
- 53. Jiang S-S, Weng D-S, Wang Q-J, Pan Ke, Zhang Y-J, Li Y-Q, et al. (2014). Galectin-3 is associated with a poor prognosis in primary hepatocellular carcinoma. J Transl Med, 12, 273.
- 54. Thijssen VL, Heusschen R, Caers J, Griffioen AW. (2015). Galectin expression in cancer diagnosis and prognosis: a systematic review. Biochim Biophys Acta, 1855, 235–247.
- 55. Chiu CG, Strugnell SS, Griffith OL, Jones SJ, Gown AM, Walker B, et al. (2010). Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol, 176, 2067-2081.
- 56. Cheng CL, Hou HA, Lee MC, Liu CY, Jhuang JY, Lai YJ, et al. (2013). Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia. Blood, 121, 3172–3180.
- 57. Prieto VG, Mourad-Zeidan AA, Melnikova V, Johnson MM, Lopez A, Diwan AH, et al. (2006). Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. Clin Cancer Res, 12(22), 6709-6715.
- 58. de Oliveira JT, Ribeiro C, Barros R, Gomes C, de Matos AJ, Reis CA, et al. (2015). Hypoxia Up-Regulates Galectin-3 in Mammary Tumor Progression and Metastasis. PLoS One, 10(7), e0134458.
- 59. Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E, Iacobelli S. (2000). Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res, 6, 1389-1393.
- 60. Saussez S, Lorfevre F, Lequeux T, Laurent G, Chantrain G, Vertongen F, et al. (2008). The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy. Oral Oncol, 44, 86-93.
- 61. Vereecken P, Zouaoui Boudjeltia K, Debray C, Awada A, Legssyer I, Sales F, et al. (2006). High serum galectin-3 in advanced melanoma: preliminary results. Clin Exp Dermatol, 31, 105-109.
- 62. Takenaka Y, Inohara H, Yoshii T, Oshima K, Nakahara S, Akahani S, et al. (2003). Malignant transformation of thyroid follicular cells by galectin-3. Cancer Lett, 195(1),111–119.
- 63. Elad-Sfadia G, Haklai R, Balan E, Kloog Y. (2004). Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. J Biol Chem, 279(33), 34922–34930.
- 64. Nakayama R, Kuroda J, Taniyama N, Yamamoto-Sugitani M, Wada S, Kiyota M, et al. (2014). Suppression of SERPINA1-albumin complex formation by galectin-3 overexpression leads to paracrine growth promotion of chronic myelogenous leukemia cells. Leuk Res, 38(1), 103–108.
- 65. Khaldoyanidi S, Glinsky V, Sikora L, Glinskii A, Mossine V, Quinn T, et al. (2003). MDA-MB-435 human breast carcinoma cell homo-and heterotypic adhesion under flow conditions is mediated in part by Thomsen-Friedenreich antigen-galectin-3 interactions. J Biol Chem, 278(6), 4127–4134.
- 66. Boscher C, Zheng Y, Lakshminarayan R, Johannes L, Dennis J, Foster L, et al. (2012). Galectin-3 protein regulates mobility of N-cadherin and GM1 ganglioside at cell-cell junctions of mammary carcinoma cells. J Biol Chem, 287(39), 32940–32952.
- 67. Boscher C, Nabi I. (2013). Galectin-3-and phospho-caveolin-1-dependent outside-in integrin signaling mediates the EGF motogenic response in mammary cancer cells. Mol Biol Cell, 24(13), 2134–2145.
- 68. Zhang D, Chen Z-G, Liu S-H, Dong Z-Q, Dalin M, Bao S-S, et al. (2013). Galectin-3 gene silencing inhibits migration and invasion of human tongue cancer cells in vitro via downregulating b-catenin. Acta Pharmacol Sin, 34(1), 176–184.
- 69. Tsuboi K, Shimura T, Masuda N, Ide M, Tsutsumi S, Yamaguchi S, et al. (2007). Galectin-3 expression in colorectal cancer: relation to invasion and metastasis. Anticancer Res, 27(4B), 2289–2296.
- 70. Kim H, Lin H, Biliran H, Raz A. (1999). Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res, 59(16), 4148–4154.
- 71. Matarrese P, Tinari N, Semeraro M, Natoli C, Iacobelli S, Malorni W. (2000). Galectin-3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis. FEBS Lett, 473(3), 311–315.
- 72. Takenaka Y, Fukumori T, Yoshii T, Oka N, Inohara H, Kim H-RC, et al. (2004). Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Mol Cell Biol, 24(10), 4395–4406.
- 73. Nangia-Makker, Wang Y, Raz T, Tait L, Balan V, Hogan V, et al. (2010). Cleavage of galectin-3 by matrix metallo proteases in duces angiogenesis in breast cancer. Int J Cancer, 127(11), 2530–2541.
- 74. Shimura T, Takenaka Y, Tsutsumi S, Hogan V, Kikuchi A, Raz A. (2004). Galectin-3, a novel binding partner of betacatenin. Cancer Res, 64(18), 6363-6367.
- 75. Song S, Mazurek N, Liu C, Sun Y, Ding QQ, Liu K, et al. (2009). Galectin-3 mediates nuclear betacatenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. Cancer Res, 69(4), 1343-1349.
- 76. Harazono Y, Kho DH, Balan V, Nakajima K, Zhang T, Hogan V, et al. (2014). Galectin-3 leads to attenuation of apoptosis through Bax heterodimerization in human thyroid carcinoma cells. Oncotarget, 5(20), 9992-10001.
- 77. Cheng YL, Huang WC, Chen CL, Tsai CC, Wang CY, Chiu WH, et al. (2011). Increased galectin-3 facilitates leukemia cell survival from apoptotic stimuli. Biochem Biophys Res Commun, 412, 334-340.
- 78. Cheong TC, Shin JY, Chun KH. (2010). Silencing of galectin-3 changes the gene expression and augments the sensitivity of gastric cancer cells to chemotherapeutic agents. Cancer Sci, 101, 94-102.
- 79. Lee YK, Lin TH, Chang CF, Lo YL. (2013). Galectin-3 silencing inhibits epirubicin-induced ATP binding cassette transporters and activates the mitochondrial apoptosis pathway via β-catenin/GSK-3β modulation in colorectal carcinoma. PLoS One, 8(11), e82478.
- 80. Califice S, Castronovo V, Van Den Brule F. (2004). Galectin-3 and cancer. Int J Oncol, 25, 983–92.
- 81. Friedl P, Alexander S. (2011). Cancer invasion and the microenvironment: plasticity and reciprocity. Cell, 147(5), 992–1009.
- 82. Nangia-Makker P, Balan V, Raz A. (2008). Regulation of tumor progression by extracellular galectin-3. Cancer Microenviron, 1(1), 43–51.
- 83. Yu LG, Andrews N, Zhao Q, McKean D, Williams JF, Connor LJ, et al. (2007). Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer associated MUC1 causes increased cancer cell endothelial adhesion. J Biol Chem, 282, 773–781.
- 84. Zhao Q, Guo X, Nash GB, Stone PC, Hilkens J, Rhodes JM, et al. (2009). Circulating galectin-3 promotes metastasis by modifying MUC1 localization on cancer cell surface. Cancer Res, 69, 6799–6806.
- 85. Zhao Q, Barclay M, Hilkens J, Guo X, Barrow H, Rhodes JM, et al. (2010). Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumor cell homotypic aggregation and prevents anoikis. Mol Cancer, 9:154.
- 86. Radosavljevic G, Jovanovic I, Majstorovic I, Mitrovic M, Lisnic V, Arsenijevic N, et al. (2011). Deletion of galectin-3 in the host attenuates metastasis of murine melanoma by modulating tumor adhesion and NK cell activity. Clin Exp Metastasis, 28(5), 451–462.
- 87. Dange MC, Srinivasan N, More SK, Bane SM, Upadhya A, Ingle AD, et al. (2014). Galectin-3 expressed on different lung compartments promotes organ specific metastasis by facilitating arrest, extravasation and organ colonization via high affinity ligands on melanoma cells. Clin Exp Metastasis, 31, 661-673.
- 88. More SK, Srinivasan N, Budnar S, Bane SM, Upadhya A, Thorat RA, et al. (2015). N-glycans and metastasis in galectin-3 transgenic mice, Biochemical and Biophysical Research Communications, 460, 302-307.
- 89. Markowska AI, Liu FT, Panjwani N. (2010). Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response. J Exp Med, 207, 1981–1993.
- 90. Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ. (2013). The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology, 138, 105–115.
- 91. Motz GT, Coukos G. (2013). Deciphering and reversing tumor immune suppression. Immunity, 39, 61–73.
- 92. Demotte N, Wieers G, VanDer Smissen P, Moser M, Schmidt C, Thielemans K, et al. (2010). A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice. Cancer Res, 70, 7476–7488.
- 93. Chen HY, Fermin A, Vardhana S, Weng IC, Lo KF, Chang EY, et al. (2009). Galectin-3 negatively regulates TCR-mediated CD4+ T-cell activation at the immunological synapse. Proc Natl Acad Sci USA, 106, 14496–14501.
- 94. Fukumori T, Takenaka Y, Yoshii T, Kim HR, Hogan V, Inohara H, et al. (2003). CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res, 63, 8302–8311.
- 95. Kouo T, Huang L, Pucsek AB, Cao M, Solt S, Armstrong T, et al. (2015). Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells. Cancer Immunol Res, 3(4), 412-423.
- 96. Tsuboi S, Sutoh M, Hatakeyama S, Hiraoka N, Habuchi T, Horikawa Y, et al. (2011). A novel strategy for evasion of NK cell immunity by tumours expressing core 2 O-glycans. EMBO J, 30, 3173–3185.
- 97. Wang JM, Cheng YQ, Shi L, Ying RS, Wu XY, Li GY, et al. (2013). KLRG1 negatively regulates natural killer cell functions through the Akt pathway in individuals with chronic hepatitis C virus infection. J Virol, 87(21), 11626-11636.
- 98. Jiang HR, Al Rasebi Z, Mensah-Brown E, Shahin A, Xu D, Goodyear CS, et al. (2009). Galectin-3 deficiency reduces the severity of experimental autoimmune encephalomyelitis. J Immunol, 182, 1167–1173.
- 99. Fermino ML, Dias FC, Lopes CD, Souza MA, Cruz ÂK, Liu FT, et al. (2013). Galectin-3 negatively regulates the frequency and function of CD4(+) CD25(+) Foxp3(+) regulatory T cells and influences the course of Leishmania major infection. Eur J Immunol, 43(7), 1806-1817.
- 100. Orentas RJ, Kohler ME, Johnson BD. (2006). Suppression of anti-cancer immunity by regulatory T cells: back to the future. Semin Cancer Biol, 16, 137–149.
- 101. Ghiringhelli F, Menard C, Terme M, Flament C, Taieb J, Chaput N, et al. (2005). CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med, 202, 1075–1085.
- 102. Murugaiyan G, Saha B. (2009). Protumor vs antitumor functions of IL-17. J Immunol, 183(7), 4169-4175.
- 103. Ikeda H, Old LJ, Schreiber RD. (2002). The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev, 13, 95–109.
- 104. Xu Z, Hurchla MA, Deng H, Uluckan O, Bu F, Berdy A, et al. (2009). Interferon-gamma targets cancer cells and osteoclasts to prevent tumor-associated bone loss and bone metastases. J Biol Chem, 284, 4658–4666.
- 105. Mitra-Kaushik S, Harding J, Hess J, Schreiber R, Ratner L. (2004). Enhanced tumorigenesis in HTLV-1 tax-transgenic mice deficient in interferon-gamma. Blood, 104, 3305–3311.
- 106. Kakuta S, Tagawa Y, Shibata S, Nanno M, Iwakura Y. (2002). Inhibition of B16 melanoma experimental metastasis by interferon-gamma through direct inhibition of cell proliferation and activation of antitumour host mechanisms. Immunology, 105, 92–100.
- 107. Wu SY, Yu JS, Liu FT, Miaw SC, Wu-Hsieh BA. (2013). Galectin-3 negatively regulates dendritic cell production of IL-23/IL-17-axis cytokines in infection by Histoplasma capsulatum. J Immunol, 190, 3427–3437.
- 108. Fermin Lee A, Chen HY, Wan L, Wu SY, Yu JS, Huang AC, et al. (2013). Galectin-3 modulates th17 responses by regulating dendritic cell cytokines. Am J Pathol, 183, 1209–1222.
- 109. Newlaczyl AU, Yu L-G. (2011). Galectin-3 – A jack-of-all-trades in cancer. Cancer Letters, 313, 123–128.
- 110. Song L, Tang J-W, Owusu L, Sun M-Z, Wu J, Zhang J. (2014). Galectin-3 in cancer. Clinica Chimica Acta, 431, 185–191.
- 111. Gabius HJ, Kayser K. (2014). Introduction to glycopathology: the concept, the tools and the perspectives. Diagn Pathol, 9:4.
Language: English
Page range: 187 - 198
Submitted on: Dec 23, 2015
Accepted on: Jan 10, 2016
Published on: Sep 24, 2016
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
Related subjects:
© 2016 Gordana D. Radosavljevic, Jelena Pantic, Ivan Jovanovic, Miodrag L. Lukic, Nebojsa Arsenijevic, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.